COLL
Collegium Pharmaceutical Inc.
$38.80
+$0.45(+1.17%)
60
Overall
80
Value
40
Tech
--
Quality
Market Cap
$1.22B
Volume
520.65K
52W Range
$23.23 - $42.29
Target Price
$44.60
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | $1.7M | $28.5M | $280.4M | $296.7M | $310.0M | $276.9M | $463.9M | $566.8M | $631.4M | ||
| Total Revenue | -- | $1.7M | $28.5M | $280.4M | $296.7M | $310.0M | $276.9M | $463.9M | $566.8M | $631.4M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | $-213.0K | $-2.6M | $-165.7M | $193.7M | $130.2M | $126.3M | $118.2M | $94.8M | $254.1M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | $1.5M | $25.9M | $114.7M | $103.0M | $179.8M | $150.6M | $209.5M | $326.2M | $377.3M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $26.9M | $95.6M | $101.3M | $-135.4M | $126.8M | $123.6M | $133.0M | $176.2M | $159.2M | $207.4M | ||
| Research & Development | $8.0M | $14.9M | $8.6M | $8.7M | $10.3M | $9.8M | $9.5M | $4.0M | -- | -- | ||
| Research Expense | $8.0M | $14.9M | $8.6M | $8.7M | $10.3M | $9.8M | $9.5M | $4.0M | -- | -- | ||
| Selling, General & Administrative | $18.9M | $80.6M | $92.8M | $126.8M | $116.4M | $113.8M | $119.0M | $172.2M | $159.2M | $210.4M | ||
| Selling & Marketing Expenses | -- | $80.6M | $92.8M | $126.8M | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $18.9M | $-25.4M | $-194.0K | -- | $116.4M | $113.8M | $119.0M | $172.2M | $159.2M | $210.4M | ||
| Salaries & Wages | -- | $-5.8M | $-7.9M | $-13.8M | $16.5M | $21.9M | $24.3M | $22.9M | $27.1M | $32.4M | ||
| Depreciation & Amortization | $-171.0K | $-258.0K | $-336.0K | $-1.1M | $731.0K | $870.0K | $1.7M | $2.7M | $3.5M | $3.9M | ||
| Depreciation & Amortization | $-171.0K | $-258.0K | $-336.0K | $-1.1M | $731.0K | $870.0K | $1.7M | $2.7M | $3.5M | $3.9M | ||
| Amortization | -- | $-397.0K | $-258.0K | $-109.8M | $29.5M | $60.7M | $67.2M | $133.7M | $142.5M | $168.3M | ||
| Other Operating Expenses | $-26.9M | $-95.8M | $-57.0K | $-64.0K | $-76.0K | $-36.0K | $-67.0K | $176.2M | $159.2M | $207.4M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-26.9M | $-94.1M | $-75.4M | $-20.7M | $-23.7M | $56.2M | $17.6M | $33.3M | $167.0M | $169.9M | ||
| EBITDA | $-26.7M | $-93.6M | $-74.0M | $91.9M | $-6.3M | $118.0M | $86.6M | $181.6M | $233.6M | $273.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $439.0K | $94.0K | -- | $20.1M | $909.0K | $28.9M | $21.0M | $63.2M | $83.3M | -- | ||
| Intinc | $-439.0K | -- | -- | -- | -- | -- | $4.7M | -- | $5.9M | $5.9M | ||
| Net Non-Operating Interest Income/Expense | $-439.0K | $-94.0K | $582.0K | $-18.4M | $-909.0K | $-28.9M | $-21.0M | $62.2M | $5.9M | $5.9M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | $1.9M | $232.0K | $12.0K | $1.0M | $15.6M | $14.0M | ||
| Other Income/Expense | $-91.0K | $-20.0K | $-28.5M | $-280.4M | $-1.9M | $-232.0K | $-12.0K | $-1.0M | $7.9M | $-5.6M | ||
| Other Special Charges | $91.0K | $20.0K | $28.5M | $280.4M | -- | -- | -- | -- | $-23.5M | $-11.3M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | $4.6M | -- | $104.1M | $15.8M | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | $-4.6M | -- | $-104.1M | $-15.8M | ||
| Other Impairment Of Capital Assets | -- | -- | $-1.8M | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-26.8M | $-94.2M | $-74.9M | $-19.0M | $-21.8M | $56.5M | $17.6M | $34.4M | $75.7M | $98.6M | ||
| Pre-Tax Income | $-27.3M | $-94.2M | $-74.9M | $-39.1M | $-22.7M | $27.6M | $-3.4M | $-28.8M | $75.7M | $98.6M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | -- | $830.0K | $-74.9M | $-3.8M | $27.6M | $29.4M | ||
| NET INCOME | ||||||||||||
| Net Income | $-27.3M | $-94.2M | $-74.9M | $-39.1M | $-22.7M | $26.8M | $71.5M | $-25.0M | $48.2M | $69.2M | ||
| Net Income (Continuing Operations) | $-27.3M | $-94.2M | $-74.9M | $-39.1M | $-22.7M | $26.8M | $71.5M | $-25.0M | $48.2M | $69.2M | ||
| Net Income (Discontinued Operations) | $-27.3M | $-94.2M | $-74.9M | $-39.1M | $-22.7M | $26.8M | $71.5M | $-25.0M | $48.2M | $69.2M | ||
| Net Income (Common Stockholders) | $-27.3M | $-94.2M | $-74.9M | $-39.1M | $-22.7M | $26.8M | $71.5M | $-25.0M | $48.2M | $69.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $110.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $26.9M | $95.4M | $98.7M | $-301.1M | $320.4M | $253.8M | $259.2M | $294.4M | $254.0M | $296.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $13.5M | $24.3M | $30.3M | $33.0M | $33.5M | $34.4M | $34.9M | $33.8M | $33.7M | $32.3M | ||
| Average Shares Outstanding (Diluted) | $20.6M | $24.3M | $30.3M | $33.8M | -- | $35.2M | $41.0M | $33.8M | $41.8M | $40.4M | ||
| Shares Outstanding | $23.5M | $29.4M | $33.0M | $33.3M | $34.1M | $34.8M | $33.4M | $34.1M | $32.0M | $31.5M | ||
| Basic EPS | $-1.48 | $-3.88 | -- | $0.27 | $-0.68 | $0.78 | $2.05 | $-0.74 | $1.43 | $2.14 | ||
| Basic EPS (Continuing Operations) | $-1.48 | -- | -- | -- | $-0.68 | $0.78 | $2.05 | $-0.74 | $1.43 | $2.14 | ||
| Diluted EPS | $-0.46 | $-3.88 | $-2.47 | $-1.19 | $-0.68 | $0.76 | $1.86 | $-0.74 | $1.29 | $1.86 | ||
| Diluted EPS (Continuing Operations) | $-0.46 | -- | -- | -- | -- | $0.76 | $1.86 | $-0.74 | $1.29 | $1.86 | ||
| OTHER METRICS | ||||||||||||
| Acquisition Expense | -- | -- | -- | -- | $14.8M | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | $280.0K | $102.0K | $96.0K | $1.0M | $141.0K | -- | ||
| Marketing Expense | -- | $-16.3M | $-11.0M | $-17.5M | -- | -- | -- | -- | -- | -- | ||
| Minority Interests | -- | -- | -- | -- | $87.4M | -- | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | -- | -- | -- | $905.0K | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $18.9M | $-25.4M | $-194.0K | -- | $116.4M | $113.8M | $119.0M | $172.2M | $159.2M | $210.4M | ||
| Other Taxes | -- | -- | -- | -- | -- | $60.7M | -- | -- | -- | -- | ||
| Provision For Gain Loss On Disposal | -- | -- | -- | $905.0K | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-112.0K | $-182.0K | $-194.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | -- | $80.6M | $92.8M | $126.8M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | $4.6M | -- | $104.1M | $15.8M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | COLL | $38.80 | +1.2% | 520.65K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Collegium Pharmaceutical Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW